Philadelphia Proton Pump Inhibitor Lawyers

Our Philadelphia Proton Pump Inhibitor Lawyers represent consumers injured by the dangerous side effects of Proton Pump Inhibitor (PPI) drugs. PPIs are prescribed by doctors around the country to treat patients’ gastrointestinal conditions such as:

  • heartburn
  • petic ulcer
  • gastro-esophageal reflux disease (GERD), and
  • dyspepsia

These drugs are available over the counter under a variety of brand names, including:

  • Aciphex (made by Eisai Co.)
  • Dexilant (made by Takeda Pharmaceuticals)
  • Nexium (made by Astra Zeneca)
  • Prevacid (made by Takeda Pharmaceuticals)
  • Prilosec (made by Astra Zeneca)
  • Protonix (made by Wyeth-Ayerst Laboratories)

PPIs work by interfering with the production of stomach acid by a PPI user’s “proton pump,” an enzyme system responsible for gastric acid secretion. Lawsuits commenced by Philadelphia Proton Pump Inhibitor Lawyers allege that the drugs’ manufacturers:

  • knew of the increased risk of serious injuries to PPI users, and
  • failed to provide adequate warnings of these risks to both physicians and consumers

The numerous health risks linked to Proton Pump Inhibitor (PPI) use include:

  • severe kidney injuries and renal failure
  • heart attack and stroke
  • heart diseases
  • bone fractures
  • dangerously low magnesium levels (hypomagnesemia)
  • hepatic encephalopathy

Kidney Injuries Linked to PPIs

The acid blocking function of Proton Pump Inhibitors (PPIs) may increase users’ chances of suffering renal (kidney) injuries. According to a study published in the April 2015 issue of CMAJ Open, people who have used Proton Pump Inhibitors (PPIs) are twice as likely as non-users to sustain acute kidney injuries. The study also found that PPI users were 3 times as likely to suffer from kidney inflammation (nephritis).

In April 2016, JASN (Journal of the American Society of Nephrology) reported the results of a study indicating a 28% increased risk in Proton Pump Inhibitor users of:

  • incident chronic kidney disease (CKD), and
  • kidney failure (end-stage renal disease)

JAMA Internal Medicine published an additional study that demonstrated:

  • a 20% to 50% increase in the risk of chronic kidney disease (CKD) in PPI users, and
  • a 44% increase in the risk of dementia

Hepatic Encephalopathy (HE) Linked to PPIs

An article published in the August 2016 issue of Hepatology reported that Proton Pump Inhibitor (PPI) use has also been linked to an increased risk of hepatic encephalopathy (HE) in cirrhosis patients. Hepatic encephalopathy (HE) is a loss of brain function that increases the risk of death in cirrhosis patients.

Contact our Philadelphia Proton Pump Inhibitor Lawyers